Ocumension Therapeutics
HKEX:1477

Watchlist Manager
Ocumension Therapeutics Logo
Ocumension Therapeutics
HKEX:1477
Watchlist
Price: 8.25 HKD 0.49% Market Closed
Market Cap: 6.7B HKD

Net Margin
Ocumension Therapeutics

-45.8%
Current
-178%
Average
4.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-45.8%
=
Net Income
-249.3m
/
Revenue
543.7m

Net Margin Across Competitors

No Stocks Found

Ocumension Therapeutics
Glance View

Market Cap
6.7B HKD
Industry
Pharmaceuticals

Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-07-10. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The firm conducts its businesses in the domestic market.

Ocumension Therapeutics Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-45.8%
=
Net Income
-249.3m
/
Revenue
543.7m
What is the Net Margin of Ocumension Therapeutics?

Based on Ocumension Therapeutics's most recent financial statements, the company has Net Margin of -45.8%.

Back to Top